by Daniel X. Thomas
EP 3 822 805 B1 relates to an apparatus system and method for adaptive-rat shifting of streaming content. It results from a divisional application of EP 05744015 later granted as EP 1 743 249 B1.
The decision to grant was published on 27.12.2023 in Bulletin 2023/52
The patent was object of actions before the EPO (opposition),
by Daniel X. Thomas
Application of G 1/24 by the Boards of Appeal of the EPO
G 1/24 has been issued on 18.06.2025. There are not a lot of decisions in which G 1/24 and the principles which it established are discussed, but it appears possible to derive some conclusions from those decisions.
This decision follows an appeal in opposition.
by Daniel X. Thomas
EP 3 167 888 B1 relates to the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by an inhibitor of complement. The product is known as eculizumab.
It stems from a third generation divisional of EP 2 359 834 A1 and EP 2 001 490 A1 filed as PCT/US2007/006606 and published under WO 2007/106585
Brief outline of the procedure before the EPO
Proprietor is Alexion Pharmaceuticals,
by Daniel X. Thomas
EP 3 666 797 B1 relates to antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (PCSK9) and methods of using and making the antigen binding proteins.
EP 3 666 797 B1 results from a divisional application of EP 2 215 124.
The case is interesting in that there exists two decisions on the same patent.
by Daniel X. Thomas
EP 3 388 490 B1 relates to decorating natural leather. It has not been opposed at the EPO.
Brief outline of the case
The proprietor, Agfa NV, sued for infringement of EP 3 388 490 B1 by a group of companies all belonging to the Gucci group before the LD Hamburg of the UPC.